Materias dentro de su búsqueda.
Mostrando 926,721 - 926,740 Resultados de 928,171 Para Buscar '"8½"', tiempo de consulta: 4.86s Limitar resultados
  1. 926721
    “…Bloods revealed rheumatoid factor 491.2, anti-RNP A ab 7.91, anti-Sm ab > 8 and anti-chromatin ab 7.3, speckled ANA positive titre of 40, Complement C4 0.08, ESR 29 and HIV negative. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    14. A severe case of connective tissue disease related interstitial lung disease in a young woman
  2. 926722
    “…Conclusions: From this 1-year study it was determined that: (1) the annualized PDC adherence rate of 0.96 was 20.25% higher than the industry standard of 0.8; (2) the Number of days work missed QoL was less after starting on a SP-D with SPMTM; and (3) the How patients feel QoL metric demonstrated that patients felt better after starting SP-D with SPMTM. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adherence of patients to oral oncolytic and neurologic specialty medications provided by a specialty pharmacy
  3. 926723
    por Alsaeid, Mohammed Awad
    Publicado 2019
    “…The selected patients were randomly allocated into 2 groups containing 20 patients each according to the study drugs; Group (D) received 5 mL (3 mL plain bupivacaine 0.5% and 2 mL (8 mg) dexamethasone), and Group (H) received 5 mL (3 mL plain bupivacaine 0.5% and 2 mL normal saline containing 300 international units (IU) hyaluronidase. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dexamethasone versus Hyaluronidase as an Adjuvant to Local Anesthetics in the Ultrasound-guided Hydrodissection of the Median Nerve for the Treatment of Carpal Tunnel Syndrome Patients
  4. 926724
    por Nan Hu
    Publicado 2018
    “…RESULTS/ANTICIPATED RESULTS: The average patient follow-up time was 9.8 years, and 18% of the women got positive Her2 test results at baseline. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2435: Accuracies of using Her2 for prognosis of breast cancer recurrence in Life After Cancer Epidemiology (LACE) Study
  5. 926725
    “…In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4–12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome
  6. 926726
    “…Recovered blastocysts showed rates of chromosome euploidy similar to the rates found in the control IVF embryos. In 11 cycles (8.2%), detectable levels of hCG were present 13 days after IUI, which regressed spontaneously in two cases and declined after an endometrial curettage in two cases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First PGT-A using human in vivo blastocysts recovered by uterine lavage: comparison with matched IVF embryo controls(†)
  7. 926727
    por Buitrago, Francisco
    Publicado 2010
    “…El uso de mascarillas simples, una OR de 0,32 (IC 95%: 0,25-0,40) y un NNT de 6 (IC 95%: 4,54-8,03) y el empleo de mascarillas N95, una OR de 0,09 (IC 95%: 0,03-0,30) y NNT de 3 (IC 95%: 2,37-4,06). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Las medidas higiénicas y las barreras son estrategias efectivas para impedir la transmisión de las infecciones víricas
  8. 926728
    “…For the prime immunisation, participants received doses of 1 × 10(7) plaque-forming unit (PFU; low-dose group) or 1 × 10(8) PFU (high-dose group) MVA-MERS-S intramuscularly. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  9. 926729
    por Ntalla, Ioanna, Weng, Lu-Chen, Cartwright, James H., Hall, Amelia Weber, Sveinbjornsson, Gardar, Tucker, Nathan R., Choi, Seung Hoan, Chaffin, Mark D., Roselli, Carolina, Barnes, Michael R., Mifsud, Borbala, Warren, Helen R., Hayward, Caroline, Marten, Jonathan, Cranley, James J., Concas, Maria Pina, Gasparini, Paolo, Boutin, Thibaud, Kolcic, Ivana, Polasek, Ozren, Rudan, Igor, Araujo, Nathalia M., Lima-Costa, Maria Fernanda, Ribeiro, Antonio Luiz P., Souza, Renan P., Tarazona-Santos, Eduardo, Giedraitis, Vilmantas, Ingelsson, Erik, Mahajan, Anubha, Morris, Andrew P., Del Greco M, Fabiola, Foco, Luisa, Gögele, Martin, Hicks, Andrew A., Cook, James P., Lind, Lars, Lindgren, Cecilia M., Sundström, Johan, Nelson, Christopher P., Riaz, Muhammad B., Samani, Nilesh J., Sinagra, Gianfranco, Ulivi, Sheila, Kähönen, Mika, Mishra, Pashupati P., Mononen, Nina, Nikus, Kjell, Caulfield, Mark J., Dominiczak, Anna, Padmanabhan, Sandosh, Montasser, May E., O’Connell, Jeff R., Ryan, Kathleen, Shuldiner, Alan R., Aeschbacher, Stefanie, Conen, David, Risch, Lorenz, Thériault, Sébastien, Hutri-Kähönen, Nina, Lehtimäki, Terho, Lyytikäinen, Leo-Pekka, Raitakari, Olli T., Barnes, Catriona L. K., Campbell, Harry, Joshi, Peter K., Wilson, James F., Isaacs, Aaron, Kors, Jan A., van Duijn, Cornelia M., Huang, Paul L., Gudnason, Vilmundur, Harris, Tamara B., Launer, Lenore J., Smith, Albert V., Bottinger, Erwin P., Loos, Ruth J. F., Nadkarni, Girish N., Preuss, Michael H., Correa, Adolfo, Mei, Hao, Wilson, James, Meitinger, Thomas, Müller-Nurasyid, Martina, Peters, Annette, Waldenberger, Melanie, Mangino, Massimo, Spector, Timothy D., Rienstra, Michiel, van de Vegte, Yordi J., van der Harst, Pim, Verweij, Niek, Kääb, Stefan, Schramm, Katharina, Sinner, Moritz F., Strauch, Konstantin, Cutler, Michael J., Fatkin, Diane, London, Barry, Olesen, Morten, Roden, Dan M., Benjamin Shoemaker, M., Gustav Smith, J., Biggs, Mary L., Bis, Joshua C., Brody, Jennifer A., Psaty, Bruce M., Rice, Kenneth, Sotoodehnia, Nona, De Grandi, Alessandro, Fuchsberger, Christian, Pattaro, Cristian, Pramstaller, Peter P., Ford, Ian, Wouter Jukema, J., Macfarlane, Peter W., Trompet, Stella, Dörr, Marcus, Felix, Stephan B., Völker, Uwe, Weiss, Stefan, Havulinna, Aki S., Jula, Antti, Sääksjärvi, Katri, Salomaa, Veikko, Guo, Xiuqing, Heckbert, Susan R., Lin, Henry J., Rotter, Jerome I., Taylor, Kent D., Yao, Jie, de Mutsert, Renée, Maan, Arie C., Mook-Kanamori, Dennis O., Noordam, Raymond, Cucca, Francesco, Ding, Jun, Lakatta, Edward G., Qian, Yong, Tarasov, Kirill V., Levy, Daniel, Lin, Honghuang, Newton-Cheh, Christopher H., Lunetta, Kathryn L., Murray, Alison D., Porteous, David J., Smith, Blair H., Stricker, Bruno H., Uitterlinden, André, van den Berg, Marten E., Haessler, Jeffrey, Jackson, Rebecca D., Kooperberg, Charles, Peters, Ulrike, Reiner, Alexander P., Whitsel, Eric A., Alonso, Alvaro, Arking, Dan E., Boerwinkle, Eric, Ehret, Georg B., Soliman, Elsayed Z., Avery, Christy L., Gogarten, Stephanie M., Kerr, Kathleen F., Laurie, Cathy C., Seyerle, Amanda A., Stilp, Adrienne, Assa, Solmaz, Abdullah Said, M., Yldau van der Ende, M., Lambiase, Pier D., Orini, Michele, Ramirez, Julia, Van Duijvenboden, Stefan, Arnar, David O., Gudbjartsson, Daniel F., Holm, Hilma, Sulem, Patrick, Thorleifsson, Gudmar, Thorolfsdottir, Rosa B., Thorsteinsdottir, Unnur, Benjamin, Emelia J., Tinker, Andrew, Stefansson, Kari, Ellinor, Patrick T., Jamshidi, Yalda, Lubitz, Steven A., Munroe, Patricia B.
    Publicado 2020
    “…We observe enrichment for cardiac muscle developmental/contractile and cytoskeletal genes, highlighting key regulation processes for atrioventricular conduction. Additionally, 8 loci not previously reported harbor genes underlying inherited arrhythmic syndromes and/or cardiomyopathies suggesting a role for these genes in cardiovascular pathology in the general population. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction
  10. 926730
    “…Patients were excluded from the trial in case of (1) known serious allergic reactions to yeast-derived products, (2) lithium carbonate therapy, (3) mechanical ventilation prior to randomization, (4) peripheral white blood cell count above 25.000/μL and/or active myeloid malignancy, (5) high dose systemic steroid therapy (> 20 mg methylprednisolone or equivalent), (6) enrolment in another investigational study, (7) pregnant or breastfeeding or (8) ferritin levels > 2000 μg/mL. INTERVENTION AND COMPARATOR: Inhaled sargramostim 125 μg twice daily for 5 days in addition to standard care. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial
  11. 926731
    “…The rationale is that TPE can remove interleukins-3, 6, 8, 10, interferon-gamma and tumor necrosis factor-alpha. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol
  12. 926732
    “…A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x10(9)/L, age >40 years and CRP >40 mg/L. Patients should be considered an appropriate subject for intervention with immunomodulatory therapies in the opinion of the investigator and be able to be maintained on venous thromboembolism prophylaxis during the inpatient dosing period, according to local guidelines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial
  13. 926733
    por Mukhina, Anna A., Kuzmenko, Natalya B., Rodina, Yulia A., Kondratenko, Irina V., Bologov, Andrei A., Latysheva, Tatiana V., Prodeus, Andrei P., Pampura, Alexander N., Balashov, Dmitrii N., Ilyina, Natalya I., Latysheva, Elena A., Deordieva, Ekaterina A., Shvets, Oksana A., Deripapa, Elena V., Abramova, Irina N., Pashenko, Olga E., Vahlyarskaya, Svetlana S., Zinovyeva, Natalya V., Zimin, Sergei B., Skorobogatova, Elena V., Machneva, Elena B., Fomina, Daria S., Ipatova, Maria G., Barycheva, Ludmila Yu., Khachirova, Ludmila S., Tuzankina, Irina A., Bolkov, Michail A., Shakhova, Natalya V., Kamaltynova, Elena M., Sibgatullina, Farida I., Guseva, Marina N., Kuznetsova, Raisa N., Milichkina, Anzhelika M., Totolian, Areg A., Kalinina, Natalia M., Goltsman, Evgenia A., Sulima, Ekatherina I., Kutlyanceva, Anastasia Yu., Moiseeva, Anna A., Khoreva, Anna L., Nesterenko, Zoya, Tymofeeva, Elena V., Ermakova, A., Proligina, Dilyara D., Kalmetieva, Linara R., Davletbaieva, Gulshat A., Mirsayapova, Irina A., Richkova, Olga A., Kuzmicheva, Ksenia P., Grakhova, Maria A., Yudina, Natalya B., Orlova, Ekaterina A., Selezneva, Olga S., Piskunova, Svetlana G., Samofalova, Tatiana V., Bukina, Tatiana V., Pechkurova, Anna D., Migacheva, N., Zhestkov, A., Barmina, Elena V., Parfenova, Natalya A., Isakova, Svetlana N., Averina, Elena V., Sazonova, Irina V., Starikova, Svetlana Yu., Shilova, Tatiana V., Asekretova, Tatiana V., Suprun, Roman N., Kleshchenko, Elena I., Lebedev, Vladimir V., Demikhova, Elena V., Demikhov, Valerii G., Kalinkina, Veronica A., Gorenkova, Alla V., Duryagina, Svetlana N., Pavlova, Tatiana B., Shinkareva, Vera M., Smoleva, Irina V., Aleksandrova, Tatiana P., Bambaeva, Zema V., Philippova, Marina A., Gracheva, Elena M., Tcyvkina, Galina I., Efremenkov, Alexey V., Mashkovskaya, D., Yarovaya, Irina V., Alekseenko, Valentina A., Fisyun, Ivan V., Molokova, Galina V., Troitskya, Ekatherina V., Piatkina, Ludmila I., Vlasova, Elena V., Ukhanova, O., Chernishova, Ekaterina G., Vasilieva, M., Laba, Olga M., Volodina, E., Safonova, Ekaterina V., Voronin, Kirill A., Gurkina, Maria V., Rumyantsev, Alexander G., Novichkova, Galina A., Shcherbina, Anna Yu.
    Publicado 2020
    “…The overall mortality rate was 9.8%. Genetic testing has been performed in 1,740 patients and genetic defects were identified in 1,344 of them (77.2%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Primary Immunodeficiencies in Russia: Data From the National Registry
  14. 926734
    “…In addition, in people with type 2 diabetes, COVID-19-related mortality was significantly higher in those with an HbA(1c) of 59 mmol/mol (7·6%) or higher than in those with an HbA(1c) of 48–53 mmol/mol (HR 1·22 [95% CI 1·15–1·30, p<0·0001] for 59–74 mmol/mol [7·6–8·9%] and 1·36 [1·24–1·50, p<0·0001] for 75–85 mmol/mol [9·0–9·9%]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study
  15. 926735
    “…Le laboratoire de virologie procédait à deux séries de PCR par jour, avec un rendu des résultats vers 13 h pour les prélèvements envoyés avant 8 h, et 19 h pour ceux envoyés avant 14 h. Une évaluation interne a été menée afin d’évaluer quantitativement et qualitativement ce dispositif. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    AMBUCOV : description d’un système de dépistage hospitalier en ambulatoire en réponse à l’épidémie de CoViD-19
  16. 926736
    “…Le LPV/r était débuté en moyenne à j8 du début des symptômes, en comprimés pour 16 patients (76 %), en sirop pour 5 (24 %). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Relation concentration-tolérance du lopinavir/ritonavir dans le traitement des COVID-19 sévères
  17. 926737
    “…En analyse multivariée, l’atteinte TDM supérieure à 50 % du parenchyme (OR = 6,3 IC95 % [2,08 ; 20,9] p = 0,001), la CRP > 100 mg/L (OR = 4,2 IC95 % [1,7 ; 10,8] p = 0,002), et la lymphopénie < 1000c/mm(3) (OR = 5,3, IC95 % [2,1 ; 14,3] p < 0,001) étaient associés à un risque de passage en réanimation indépendamment de l’âge. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Description et facteurs associés à la gravité d’un cluster original COVID-19
  18. 926738
    “…Ils présentaient plus fréquemment une toux (73,3 % vs 47,9 %, p < 0,001), des diarrhées (30,0 % vs 12,5 % p < 0,001), des difficultés à respirer (64,4 % vs 48,6 %, p = 0,004), une fatigue (71,7 % vs 57,6 %, p = 0,009), une anosmie (8,9 % vs 0,7 %, p < 0,001), une agueusie (11,7 % vs 1,4 %, p < 0,001), et un taux plasmatique de CRP plus élevé (médiane 107,0 mg/L vs 49,2, p < 0,001). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Les caractéristiques des patients atteints d’infection à SARS-CoV-2 influencent-elles leur délai d’admission en hospitalisation ?
  19. 926739
    “…Furthermore, severe COVID-19 cases had a higher risk to have lymphopenia (RR =1.66, 95%CI: 1.26;2.20; P-value:0.002), thrombocytopenia (RR = 1.86, 95%CI: 1.59;2.17; P-value: < 0.001), elevated procalcitonin level (RR = 2.94, 95%CI: 2.09–4.15; P-value:< 0.001), CRP (RR =1.41,95%CI: 1.17–1.70; P-value:0.003), ASAT(RR =2.27, 95%CI: 1.76;2.94; P-value:< 0.001), CK(RR = 2.61, 95%CI: 1.35;5.05; P-value: 0.01), Creatininemia (RR = 3.66, 95%CI: 1.53;8.81; P-value: 0.02) and LDH blood level (RR = 2.03, 95%CI: 1.42;290; P-value: 0.003). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)
  20. 926740
    “…Compared to pregnant women without covid-19, those with the disease had increased odds of maternal death (odds ratio 6.09, 95% confidence interval 1.82 to 20.38; I(2)=76.6%), of admission to the intensive care unit (5.41, 3.59 to 8.14; I(2)=57.0%), caesarean section (1.17, 1.01 to 1.36; I(2)=80.3%), and of preterm birth (1.57, 1.36 to 1.81; I(2)=49.3%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
Herramientas de búsqueda: RSS